文献速递前列腺癌男科与性医学

前列腺癌男性的心血管风险:RADICAL PC 研究解读

Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study.
PubMed 文献 · J Urol · 2020-01-03

RADICAL PC 研究前瞻性纳入加拿大 16 个中心 2,492 例连续前列腺癌男性(平均年龄 68 岁),用 Framingham 风险评分评估心血管风险。结果显示 69% 为高心血管风险,且计划使用雄激素剥夺治疗者基线 Framingham 评分更高,但校正混杂因素后该关联消失。

要点

  • 约三分之二前列腺癌男性为高心血管风险(Framingham 评分)。
  • 计划使用雄激素剥夺治疗者基线心血管风险更高,但由混杂因素解释。
  • 前列腺癌患者应常规评估心血管风险因素。

核心结论

  • 约三分之二前列腺癌男性为高心血管风险。
  • 计划使用雄激素剥夺治疗与基线心血管风险因素呈正相关,但该关联可由混杂因素解释。

研究设计与样本

  • 前瞻性队列研究,纳入加拿大 16 个中心的 2,492 例连续前列腺癌男性,平均年龄 68 岁,为新诊断或首次计划处方雄激素剥夺治疗者。
  • 采用 Framingham 风险评分评估心血管风险。

主要发现

  • 92% 为新诊断前列腺癌(中危 41%,高危 50%)。
  • 58% 为当前或既往吸烟者,22% 有已知心血管疾病,16% 有糖尿病,45% 有高血压,31% 体质指数≥30 kg/m2,24% 体力活动水平低。
  • 平均握力为 37.3 kg,69% 的 Framingham 风险评分符合高心血管风险。
  • 计划接受雄激素剥夺治疗者 Framingham 风险评分高于不打算接受者,校正混杂因素后该风险关联消失。

关键数值与推荐

  • Framingham 风险评分用于定义高心血管风险,69% 的参与者符合高心血管风险。
  • 计划使用雄激素剥夺治疗与基线心血管风险因素正相关,但校正混杂因素后关联无统计学意义。

临床怎么用

  • 对前列腺癌患者应常规评估心血管风险因素,尤其计划使用雄激素剥夺治疗者。
  • 不能仅因计划使用雄激素剥夺治疗而推断心血管风险升高,需考虑混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We describe the cardiovascular risk profile in a representative cohort of patients with prostate cancer treated with or without androgen deprivation therapy. MATERIALS AND METHODS: We prospectively characterized in detail 2,492 consecutive men (mean age 68 years) with prostate cancer (newly diagnosed or with a plan to prescribe androgen deprivation therapy for the first time) from 16 Canadian sites. Cardiovascular risk was estimated by calculating Framingham risk scores. RESULTS: Most men (92%) had new prostate cancer (intermediate risk 41%, high risk 50%). The highest level of education achieved was primary school in 12%. Most (58%) were current or former smokers, 22% had known cardiovascular disease, 16% diabetes, 45% hypertension, 31% body mass index 30 kg/m2 or greater, 24% low levels of physical activity, mean handgrip strength was 37.3 kg and 69% had a Framingham risk score consistent with high cardiovascular risk. Participants in whom androgen deprivation therapy was planned had higher Framingham risk scores than those not intending to receive androgen deprivation therapy, and this risk was abolished after adjustment for confounders. CONCLUSIONS: Two-thirds of men with prostate cancer are at high cardiovascular risk. There is a positive association between a plan to use androgen deprivation therapy and baseline cardiovascular risk factors. However, this association is explained by confounding factors.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Leong DP, Fradet V, Shayegan B, et al. Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study. J Urol. 2020. PMID: 31899651. doi:10.1097/JU.0000000000000714

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。